Abdul Mannan – Breaking in Haem: Andexanet Alfa Withdrawn from US Market
Abdul Mannan, Consultant Haematologist at Betsi Cadwaladr University Health Board, shared on LinkedIn:
“Breaking in Haem: Andexanet Alfa Withdrawn from US Market
A major shift in anticoagulation reversal is happening. AstraZeneca is withdrawing the BLA for Andexxa (andexanet alfa), effective Dec 22, 2025.
Why is this happening? Let us make it simple
It’s a case of “Biochemistry vs. Clinical Outcome.”
We failed to bridge the gap from Accelerated Approval (2018) to Traditional Approval.
The Data Dilemma:
Efficacy: It worked. In ANNEXA-4, it slashed anti-Factor Xa activity (e.g., Apixaban levels dropped from ~150 to ~11 ng/mL).
Safety: The ANNEXA-I trial showed a worrying signal. Thrombotic events were 14.6% with Andexanet vs 6.9% with usual care (PCC).
What now?
We return to the basics. For life-threatening bleeding on apixaban or rivaroxaban, we rely on Prothrombin Complex Concentrates (PCC).
A reminder that even ‘targeted’ antidotes must prove they don’t cause more harm than the bleeding they are trying to stop.”
More posts featuring Abdul Mannan on Hemostasis Today.
-
Dec 20, 2025, 18:30Kate Scrivener on Cochrane Review: 2025 Ends With a Big Milestone!
-
Dec 20, 2025, 18:15Shekher Bose on AstraZeneca’s Voluntary Withdrawal of Andexxa
-
Dec 20, 2025, 17:10Mina Adel Nagi on the Future of ESR Testing with HORIBA’s CoRA Technology
-
Dec 20, 2025, 16:50Geert Verheyden on Advancing Stroke Rehabilitation Through Collaboration and Innovation
-
Dec 20, 2025, 16:26Dirk Sibbing on Antithrombotic Drugs for ACS in Women
-
Dec 20, 2025, 16:13Akshat Jain Explains VWF/FVIII Prophylaxis in Children Under 6
-
Dec 20, 2025, 15:49Manuel Requena Shares The Results of the RESISTANT International Registry
-
Dec 20, 2025, 13:49Harshal Kale: Wishing Our Community a Bright Start to 2026
-
Dec 20, 2025, 12:23Healthcare is a Human Right: Strengthening Blood Donation in Armenia